Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Research Article

Investigation of the Relationship among Cortisol, Pro-inflammatory Cytokines, and the Degradation of Tryptophan into Kynurenine in Patients with Major Depression and Suicidal Behavior

Author(s): Amel Messaoud, Mensi Rym, Douki Wahiba, Fadoua Neffati, Mohamed Fadhel Najjar, Gabriella Gobbi, Mirko Manchia, Flavia Valtorta, Gaha Lotfi* and Stefano Comai*

Volume 22, Issue 25, 2022

Published on: 12 October, 2021

Page: [2119 - 2125] Pages: 7

DOI: 10.2174/1568026621666210909160210

Price: $65

Open Access Journals Promotions 2
Abstract

Background: The increased degradation of tryptophan (Trp) along the kynurenine (Kyn) pathway due to inflammation and/or activation of the hypothalamic-pituitary–adrenal (HPA) axis has been reported among the biological factors involved in the pathophysiology of major depressive disorder (MDD) and suicide. However, the interaction among these multiple factors is not yet completely clarified.

Methods: We studied plasma levels of Trp, Kyn, cortisol and proinflammatory cytokines (IL-1, IL- 6, IL-12, IL-20) and calculated the ratio Kyn/Trp as an index of the breakdown of Trp into Kyn in 31 suicidal MDD patients and 67 non-suicidal MDD patients.

Result: We confirmed that suicidal MDD patients have reduced plasma Trp, higher Kyn and Kyn/Trp ratio, and no difference in cortisol levels than non-suicidal MDD patients. IL-1 and IL-12 levels were significantly higher in suicidal MDD than in non-suicidal MDD (p=0.034 and p=0.023, respectively), whereas Il-6 and IL-20 levels were equal in the two groups. The Kyn/Trp ratio was positively correlated with a pro-inflammatory cytokines index (r=0.309, p=0.002) and cortisol (r=0.368, p=0.001). Notably, the variance in the Kyn/Trp ratio explained by the model including both cortisol and inflammatory parameters as dependent variables, substantially improved compared with the models in which the two parameters were considered separately.

Conclusion: These findings show that both cortisol and proinflammatory cytokines are involved in the enhanced breakdown of Trp into Kyn occurring in suicidal MDD patients, thus adding new knowledge on the biological mechanisms leading to the activation of the Kyn pathway in MDD and suicide.

Keywords: Suicide, Major depression, Inflammatory cytokines, Cortisol, Kynurenine/tryptophan ratio, Hypothalamicpituitary- adrenal (HPA) axis.

Graphical Abstract
[1]
Henriksson, M.M.; Aro, H.M.; Marttunen, M.J.; Heikkinen, M.E.; Isometsä, E.T.; Kuoppasalmi, K.I.; Lönnqvist, J.K. Mental disorders and comorbidity in suicide. Am. J. Psychiatry, 1993, 150(6), 935-940.
[http://dx.doi.org/10.1176/ajp.150.6.935] [PMID: 8494072]
[2]
Lesage, A.D.; Boyer, R.; Grunberg, F.; Vanier, C.; Morissette, R.; Ménard-Buteau, C.; Loyer, M. Suicide and mental disorders: A case-control study of young men. Am. J. Psychiatry, 1994, 151(7), 1063-1068.
[http://dx.doi.org/10.1176/ajp.151.7.1063] [PMID: 7503818]
[3]
Dong, M.; Wang, S.B.; Li, Y.; Xu, D.D.; Ungvari, G.S.; Ng, C.H.; Chow, I.H.I.; Xiang, Y.T. Prevalence of suicidal behaviors in patients with major depressive disorder in China: A comprehensive meta-analysis. J. Affect. Disord., 2018, 225, 32-39.
[http://dx.doi.org/10.1016/j.jad.2017.07.043] [PMID: 28779680]
[4]
Manchia, M.; Carpiniello, B.; Valtorta, F.; Comai, S. Serotonin dysfunction, aggressive behavior, and mental illness: exploring the link using a dimensional approach. ACS Chem. Neurosci., 2017, 8(5), 961-972.
[http://dx.doi.org/10.1021/acschemneuro.6b00427] [PMID: 28378993]
[5]
Messaoud, A.; Mensi, R.; Douki, W.; Neffati, F.; Najjar, M.F.; Gobbi, G.; Valtorta, F.; Gaha, L.; Comai, S. Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide. World J. Biol. Psychiatry, 2019, 20(9), 703-711.
[http://dx.doi.org/10.1080/15622975.2018.1468031] [PMID: 29683396]
[6]
Myint, A.M.; Kim, Y.K. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2014, 48, 304-313.
[http://dx.doi.org/10.1016/j.pnpbp.2013.08.008] [PMID: 24184687]
[7]
Myint, A.M.; Kim, Y.K.; Verkerk, R.; Scharpé, S.; Steinbusch, H.; Leonard, B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord., 2007, 98(1-2), 143-151.
[http://dx.doi.org/10.1016/j.jad.2006.07.013] [PMID: 16952400]
[8]
Brundin, L.; Sellgren, C.M.; Lim, C.K.; Grit, J.; Pålsson, E.; Landén, M.; Samuelsson, M.; Lundgren, K.; Brundin, P.; Fuchs, D.; Posto-lache, T.T.; Traskman-Bendz, L.; Guillemin, G.J.; Erhardt, S. An enzyme in the kynurenine pathway that governs vulnerability to suicid-al behavior by regulating excitotoxicity and neuroinflammation. Transl. Psychiatry, 2016, 6(8), e865.
[http://dx.doi.org/10.1038/tp.2016.133] [PMID: 27483383]
[9]
Serafini, G.; Adavastro, G.; Canepa, G.; Capobianco, L.; Conigliaro, C.; Pittaluga, F.; Murri, M.B.; Valchera, A.; De Berardis, D.; Pompili, M.; Lindqvist, D.; Brundin, L.; Amore, M. Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and sui-cidality: a systematic review. CNS Neurol. Disord. Drug Targets, 2017, 16(4), 440-453.
[http://dx.doi.org/10.2174/1871527316666170413110605] [PMID: 28412922]
[10]
Bryleva, E.Y.; Brundin, L. Suicidality and activation of the kynurenine pathway of tryptophan metabolism. Curr. Top. Behav. Neurosci., 2017, 31, 269-284.
[http://dx.doi.org/10.1007/7854_2016_5] [PMID: 27221623]
[11]
Bryleva, E. Y.; Brundin, L. Kynurenine pathway metabolites and suicidality. Neuropharmacology, 2017, 112(Pt B), 324-330.
[http://dx.doi.org/10.1016/j.neuropharm.2016.01.034]
[12]
Stockmeier, C.A. Neurobiology of serotonin in depression and suicide. Ann. N. Y. Acad. Sci., 1997, 836(1), 220-232.
[http://dx.doi.org/10.1111/j.1749-6632.1997.tb52362.x] [PMID: 9616801]
[13]
Turecki, G.; Brent, D.A.; Gunnell, D.; O’Connor, R.C.; Oquendo, M.A.; Pirkis, J.; Stanley, B.H. Suicide and suicide risk. Nat. Rev. Dis. Primers, 2019, 5(1), 74.
[http://dx.doi.org/10.1038/s41572-019-0121-0] [PMID: 31649257]
[14]
Mann, J.J. The neurobiology of suicide. Nat. Med., 1998, 4(1), 25-30.
[http://dx.doi.org/10.1038/nm0198-025] [PMID: 9427602]
[15]
Badawy, A.A.; Guillemin, G. The plasma [kynurenine]/[trypto-] phan] ratio and indoleamine 2,3-dioxygenase: time for appraisal. Int. J. Tryptophan Res., 2019, 12, 1178646919868978.
[http://dx.doi.org/10.1177/1178646919868978] [PMID: 31488951]
[16]
Comai, S.; Bertazzo, A.; Brughera, M.; Crotti, S. Tryptophan in health and disease. Adv. Clin. Chem., 2020, 95, 165-218.
[http://dx.doi.org/10.1016/bs.acc.2019.08.005] [PMID: 32122523]
[17]
Schwarcz, R.; Bruno, J.P.; Muchowski, P.J.; Wu, H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci., 2012, 13(7), 465-477.
[http://dx.doi.org/10.1038/nrn3257] [PMID: 22678511]
[18]
Achtyes, E.; Keaton, S.A.; Smart, L.; Burmeister, A.R.; Heilman, P.L.; Krzyzanowski, S.; Nagalla, M.; Guillemin, G.J.; Escobar Galvis, M.L.; Lim, C.K.; Muzik, M.; Postolache, T.T.; Leach, R.; Brundin, L. Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression. Brain Behav. Immun., 2020, 83, 239-247.
[http://dx.doi.org/10.1016/j.bbi.2019.10.017] [PMID: 31698012]
[19]
Bay-Richter, C.; Linderholm, K.R.; Lim, C.K.; Samuelsson, M.; Träskman-Bendz, L.; Guillemin, G.J.; Erhardt, S.; Brundin, L. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav. Immun., 2015, 43, 110-117.
[http://dx.doi.org/10.1016/j.bbi.2014.07.012] [PMID: 25124710]
[20]
Erhardt, S.; Lim, C.K.; Linderholm, K.R.; Janelidze, S.; Lindqvist, D.; Samuelsson, M.; Lundberg, K.; Postolache, T.T.; Träskman-Bendz, L.; Guillemin, G.J.; Brundin, L. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology, 2013, 38(5), 743-752.
[http://dx.doi.org/10.1038/npp.2012.248] [PMID: 23299933]
[21]
Trepci, A.; Sellgren, C.M.; Pålsson, E.; Brundin, L.; Khanlarkhani, N.; Schwieler, L.; Landén, M.; Erhardt, S. Central levels of tryptophan metabolites in subjects with bipolar disorder. Eur. Neuropsychopharmacol., 2021, 43, 52-62.
[PMID: 33339712]
[22]
Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 1960, 23, 56-62.
[http://dx.doi.org/10.1136/jnnp.23.1.56] [PMID: 14399272]
[23]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision; DSM-IV-TR: Washington, DC, 2000, p. 4.
[24]
Comai, S.; Bertazzo, A.; Vachon, J.; Daigle, M.; Toupin, J.; Côté, G.; Turecki, G.; Gobbi, G. Tryptophan via serotonin/kynurenine path-ways abnormalities in a large cohort of aggressive inmates: markers for aggression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 70, 8-16.
[http://dx.doi.org/10.1016/j.pnpbp.2016.04.012] [PMID: 27117820]
[25]
Nazzari, S.; Fearon, P.; Rice, F.; Ciceri, F.; Molteni, M.; Frigerio, A. Neuroendocrine and immune markers of maternal stress during pregnancy and infant cognitive development. Dev. Psychobiol., 2020, 62(8), 1100-1110.
[http://dx.doi.org/10.1002/dev.21967] [PMID: 32232990]
[26]
Brundin, L.; Bryleva, E.Y.; Thirtamara Rajamani, K. Role of inflammation in suicide: from mechanisms to treatment. Neuropsychopharmacology, 2017, 42(1), 271-283.
[http://dx.doi.org/10.1038/npp.2016.116] [PMID: 27377015]
[27]
Urata, Y.; Koga, K.; Hirota, Y.; Akiyama, I.; Izumi, G.; Takamura, M.; Nagai, M.; Harada, M.; Hirata, T.; Yoshino, O.; Kawana, K.; Fujii, T.; Osuga, Y. IL-1β increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells. Am. J. Reprod. Immunol., 2014, 72(5), 496-503.
[http://dx.doi.org/10.1111/aji.12282] [PMID: 24974860]
[28]
Walker, A.K.; Budac, D.P.; Bisulco, S.; Lee, A.W.; Smith, R.A.; Beenders, B.; Kelley, K.W.; Dantzer, R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology, 2013, 38(9), 1609-1616.
[http://dx.doi.org/10.1038/npp.2013.71] [PMID: 23511700]
[29]
Park, S.E.; Lawson, M.; Dantzer, R.; Kelley, K.W.; McCusker, R.H. Insulin-like growth factor-I peptides act centrally to decrease depres-sion-like behavior of mice treated intraperitoneally with lipopolysaccharide. J. Neuroinflammation, 2011, 8, 179.
[http://dx.doi.org/10.1186/1742-2094-8-179] [PMID: 22189158]
[30]
O’Connor, D.B.; Gartland, N.; O’Connor, R.C. Stress, cortisol and suicide risk. Int. Rev. Neurobiol., 2020, 152, 101-130.
[31]
O’Connor, D.B.; Ferguson, E.; Green, J.A.; O’Carroll, R.E.; O’Connor, R.C. Cortisol levels and suicidal behavior: A meta-analysis. Psychoneuroendocrinology, 2016, 63, 370-379.
[http://dx.doi.org/10.1016/j.psyneuen.2015.10.011] [PMID: 26555430]
[32]
Clark, S.M.; Pocivavsek, A.; Nicholson, J.D.; Notarangelo, F.M.; Langenberg, P.; McMahon, R.P.; Kleinman, J.E.; Hyde, T.M.; Stiller, J.; Postolache, T.T.; Schwarcz, R.; Tonelli, L.H. Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. J. Psychiatry Neurosci., 2016, 41(6), 386-394.
[http://dx.doi.org/10.1503/jpn.150226] [PMID: 27070351]
[33]
Miller, C.L.; Llenos, I.C.; Dulay, J.R.; Weis, S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cin-gulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res., 2006, 1073-1074, 25-37.
[http://dx.doi.org/10.1016/j.brainres.2005.12.056] [PMID: 16448631]
[34]
Ducasse, D.; Olié, E.; Guillaume, S.; Artéro, S.; Courtet, P. A meta-analysis of cytokines in suicidal behavior. Brain Behav. Immun., 2015, 46, 203-211.
[http://dx.doi.org/10.1016/j.bbi.2015.02.004] [PMID: 25678163]
[35]
Tuglu, C.; Kara, S.H.; Caliyurt, O.; Vardar, E.; Abay, E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl.), 2003, 170(4), 429-433.
[http://dx.doi.org/10.1007/s00213-003-1566-z] [PMID: 12955291]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy